Olympus Companions has $4 billion to speculate after the center market non-public fairness agency wrapped up fundraising for its newest flagship fund. The agency stated Wednesday that its eighth pool got here in at $3.5 billion, and jumped to $4 billion with the inclusion of coinvestments from its LPs and anticipated reinvestments, in response to a March 26 letter to Olympus buyers. Olympus had set a $4 billion arduous cap for Fund VIII, the utmost the fund was permitted to lift from buyers.
Olympus spent roughly a 12 months advertising for its eighth pool, which raised 15% greater than its prior fund. Olympus Development Fund VII collected $3.04 billion in late 2017.
Earlier this month, Fortune reported that Olympus fund VIII had raised $2.87 billion.
Olympus is the PE agency from Chairman and CEO Rob Morris, who can be its founder. The agency invests in enterprise providers, meals providers, shopper merchandise, healthcare providers, monetary providers, industrial providers and manufacturing. Since launching in 1988, Olympus has raised $12 billion in capital. The agency has additionally returned $6 billion to buyers over the previous three years, together with $3 billion in 2024, Fortune has reported.
Morris, within the letter, mentioned the tariff-driven coverage of the Trump administration, which has brought about rampant inventory market volatility, and fears of a recession. Morris stated non-public fairness managers ought to do their greatest to keep away from the “incoming missiles” of tariffs. For companies with a provide chain closely depending on tariff targets, he suggested diversifying to safer geographies or pursuing tariff exempted options. “There are many other tactical moves, but no foolproof plan to completely avoid the economic storm a trade war could ignite,” Morris wrote within the letter.
Fund VIII started investing in January and has up to now accomplished two transactions. In January, Olympus acquired Accelevation, a supplier of infrastructure services to the information middle market, for $455 million. The PE agency additionally scooped up generic drug maker PAI Pharma for $605 million in February. The offers had been “the fastest Olympus has purchased two investments at the advent of a Fund,” in response to the letter.
This story was initially featured on Fortune.com
